Halozyme therapeutics, inc.HALO.US Overview
HALO Overall Performance
HALO AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
HALO Current Performance
0.47%
Halozyme therapeutics, inc.
-0.47%
Avg of Sector
-0.64%
S&P500
HALO Key Information
HALO Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
HALO Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
HALO Profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Price of HALO
HALO FAQ
When is HALO's latest earnings report released?
The most recent financial report for Halozyme therapeutics, inc. (HALO) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HALO's short-term business performance and financial health. For the latest updates on HALO's earnings releases, visit this page regularly.
Where does HALO fall in the P/E River chart?
According to historical valuation range analysis, Halozyme therapeutics, inc. (HALO)'s current price-to-earnings (P/E) ratio is 12.76, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of HALO?
According to the latest financial report, Halozyme therapeutics, inc. (HALO) reported an Operating Profit of 202.44M with an Operating Margin of 62.15% this period, representing a growth of 72.68% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is HALO's revenue growth?
In the latest financial report, Halozyme therapeutics, inc. (HALO) announced revenue of 325.72M, with a Year-Over-Year growth rate of 40.79%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does HALO have?
At the end of the period, Halozyme therapeutics, inc. (HALO) held Total Cash and Cash Equivalents of 61.86M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does HALO go with three margins increasing?
In the latest report, Halozyme therapeutics, inc. (HALO) achieved the “three margins increasing” benchmark, with a gross margin of 85.8%%, operating margin of 62.15%%, and net margin of 50.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HALO's profit trajectory and future growth potential.
Is HALO's EPS continuing to grow?
According to the past four quarterly reports, Halozyme therapeutics, inc. (HALO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.36. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of HALO?
Halozyme therapeutics, inc. (HALO)'s Free Cash Flow (FCF) for the period is 98.15M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 84.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of HALO?
The latest valuation data shows Halozyme therapeutics, inc. (HALO) has a Price-To-Earnings (PE) ratio of 12.76 and a Price/Earnings-To-Growth (PEG) ratio of 0.23. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.